# PepGen Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
Canonical URL: https://biopharmsignal.com/news/PEPG/pepgen-reports-first-quarter-2026-financial-results-and-recent-corporate-highlights
Ticker: PEPG
Company: PepGen
Source: PepGen
Published: 2026-05-12 20:05 EST
Original Source URL: https://investors.pepgen.com
## Summary

– FREEDOM2-DM1 5 mg/kg cohort demonstrated favorable safety, splicing and vHOT data, with the totality of results supporting the potential of the ongoing 10 mg/kg dose cohort – – The FREEDOM2 10 mg/kg cohort is fully enrolled, with data on track for 2H 2026 – – Well-funded with $132.3M of cash as

## Article Body
– FREEDOM2-DM1 5 mg/kg cohort demonstrated favorable safety, splicing and vHOT data, with the totality of results supporting the potential of the ongoing 10 mg/kg dose cohort – – The FREEDOM2 10 mg/kg cohort is fully enrolled, with data on track for 2H 2026 – – Well-funded with $132.3M of cash as
## Recent Company News
- 2026-05-21 11:00 EST — [PepGen Announces Presentations at the 15th International Myotonic Dystrophy Consortium Highlighting Clinical Data from the PGN-EDODM1 Program](https://biopharmsignal.com/news/PEPG/pepgen-announces-presentations-at-the-15th-international-myotonic-dystrophy-consortium-highlighting-clinical-data-from-the-pgn-edodm1-program) — Source: PepGen
- 2026-05-12 20:05 EST — [PepGen Reports First Quarter 2026 Financial Results and Recent Corporate Highlights](https://biopharmsignal.com/news/PEPG/pepgen-reports-first-quarter-2026-financial-results-and-recent-corporate-highlights) — Source: PepGen
- 2026-03-30 20:05 EST — [PepGen Announces Topline Results from Lowest Dose (5 mg/kg) MAD Cohort in the Ongoing Phase 2 FREEDOM2 Study Demonstrating Favorable Safety, Splicing and vHOT Data](https://biopharmsignal.com/news/PEPG/pepgen-announces-topline-results-from-lowest-dose-5-mg-kg-mad-cohort-in-the-ongoing-phase-2-freedom2-study-demonstrating-favorable-safety-splicing-and-vhot-data) — Source: PepGen
- 2026-03-04 21:05 EST — [PepGen Reports Fourth Quarter and Year-End 2025 Financial Results and Recent Corporate Highlights](https://biopharmsignal.com/news/PEPG/pepgen-reports-fourth-quarter-and-year-end-2025-financial-results-and-recent-corporate-highlights) — Source: PepGen
- 2026-03-04 21:03 EST — [PepGen Announces Regulatory Updates on FREEDOM2](https://biopharmsignal.com/news/PEPG/pepgen-announces-regulatory-updates-on-freedom2) — Source: PepGen
## Related News
- 2026-07-21 12:05 EST — VRCA — [Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522)
- 2026-07-21 11:30 EST — ABEO — [Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®](https://biopharmsignal.com/news/ABEO/cincinnati-children-s-activated-as-the-seventh-qualified-treatment-center-for-ze-8382d043)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)